

IASLC



INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

Financial/Commercial Relationships Disclosures



CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this live activity for a maximum of 11 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Financial/Commercial Relationships DISCLOSURES

All individuals able to influence or control content of any CME certified activity that will be presented were required to complete a Financial Relationships/Conflicts of Interest Disclosure Form prior to the live activity.

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected.

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest *were identified, reviewed and resolved from* all individuals involved in the development or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The following Financial Disclosures are from the, reviewers, speakers, planning committee members (et.al.) their spouse/life partner have disclosed regarding financial interest/arrangement or affiliation with any commercial interests that produce, market, re-sell, or distribute healthcare goods or services for patients that are relevant to this presentation(s) or that have provided commercial support for this continuing medical education activity.



CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Live activity for a maximum of 11 AMA *PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FINANCIAL SUPPORT

This educational activity was commercially supported by: Abbvie, Merck, Bristol-Myers Squibb, Genentech, Incyte, Pfizer, Boehringer Ingelheim, Astrazeneca, Novartis, Takeda, Astellas, Tempus. IASLC would like to thank all commercial supporters for this meeting.

GOAL & PURPOSE

This symposium is an educational and scientific event which, due to its multidisciplinary nature, will cover all aspects of the management of lung cancers, mesothelioma, thymic and other thoracic malignancies.

Participants will learn about tobacco control and smoking cessation programs and how to implement them in their daily practice. Participants will update their knowledge on early detection and screening.

The symposium will provide lectures on accurate diagnosis including molecular diagnosis, state-of-the-art treatment of thoracic malignancies, and recent diagnostic and therapeutic advances. Participants will learn about palliative care and its implementation in daily practice.

Participants will be informed about the possibilities for continuous medical education. They will learn about clinical trial designs and how to become successful investigators of co-operative research groups. The Conference will also allow participants to be better informed about patient support and advocacy groups.

TARGET AUDIENCE

This CME activity is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

LEARNING OBJECTIVES

- Examine evidence-based therapeutic regimens for early stage and locally advanced NSCLC.
- Distinguish evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics.



- Define best practices regarding the application of targeted therapies for metastatic NSCLC in frontline and then subsequent settings following acquired resistance to the targeted therapy.
 - Describe current and emerging immunotherapy strategies in the context of clinical trials findings and patient selection in metastatic NSCLC.
 - Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen.
 - Review the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in non-academic settings.
- Illustrate the molecular pathways that hold promise for therapeutic intervention.
- Outline current therapeutic approaches for limited and extensive small cell lung cancer (SCLC).
- Describe current therapeutic approaches for patients with mesothelioma and thymoma.
- Predict optimal and best practice approaches for supportive and palliative care of patients with thoracic cancers.
- Evaluate the support and survivorship resources available for lung cancer patients and their families.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

**Reviewer****Alex Adjei, MD, PhD-**

Nothing to disclose

Planners**Pia Hirsch**

Nothing to disclose

Carlos Ferreira

Nothing to disclose

Invited Speakers Disclosures

Ahmed, Shahid	Nothing to disclose.
Appel, Sarit	Nothing to disclose.
Arenburg, Doug	Supported/Contracted Research/Grant: Covidien; clinical trial enrollment contract for registry trial of navigation bronchoscopy. and VisionGate: Medical advisory panel for development of early lung cancer detection tools. and Nucleix; Advisory panel for development of early lung cancer detection biomarkers. Michigan Department of Community Health: Grant funding for Health Systems Change for Tobacco Cessation and Lung Cancer screening.
Ahmed, Osmanuddin	Nothing to disclose.
Backhus, Leah	Nothing to disclose.
Bestvina, Christine	Nothing to disclose.
Carlson, Alexander	Nothing to disclose.
Chaft, Jamie	Speaker/Advisory Board & Consultant for: BMS, AZ, Merck, Genetech.
Chalmers, Anna	Nothing to disclose.
Chen, Tianxiang	Nothing to disclose.
Chmura, Steven	Nothing to disclose.
Chun, Stephen	Nothing to disclose.
Dacic, Sanja	Nothing to disclose.
DeCamp, Malcolm	Nothing to disclose.
Decker, Roy	Nothing to disclose.
Diehn, Max	Consultant: Roche
Donington, Jessica	Nothing to disclose.
Farrell, Matthew	Nothing to disclose.
Feldman, Larry	Nothing to disclose.
Feliciano, Joy	Speakers/Advisory Board: Takeda.



Fidler, Mari Jo	Merck: speaker bureau, invited speaker; Abbvie: advisory board; Astrazeneca: advisory board; Genentech: husband consultant, majority of income from Genentech. Genentech: speakers bureau; Celgene: speaker bureau; Takeda: advisory board
Freeman-Daly, Janet	Nothing to disclose.
Friedman, Lyssa	Consultant: OncoCyte Corporation.
Gaspar, Laurie	Nothing to disclose.
Gerber, David	Nothing to disclose.
Gillespie, Colin	Disclosure onsite.
Hedge, Aparna	Nothing to disclose.
Hellmann, Mathew	Advisory Boards: Merck, BMS, Genentech, AstraZeneca, Janssen, Novartis. Supported research grants: BMS, Genentech
Hensing, Thomas	Nothing to disclose.
Heymach, John	Honoraria: Genetech, Astrazeneca, BI and Lilly
Hirsch, Fred	Speaker/Advisory Board: AstraZeneca, Genentech, BMS, Lilly, Abbvie.
Horn, Leora	Speakers/Advisory Board: Roche-Genetech, Abbvie, BMS, Lilly, Astra Zeneca, Merck, Xcovery. Steering Committee BMS, Merck, Janssen.
Iyengar, Puneeth	Nothing to disclose.
Katz, Sharyn	Nothing to disclose.
Kruser, Timothy	Speaker/Advisory Board: Abbvie, Inc; Consultant: Varian Medical Systems
Land, Stephanie	Nothing to disclose.
Malec, Monica	Nothing to disclose.
Martin, Linda	Nothing to disclose.
McCall, Bretta	Nothing to disclose.
Mehran, Reza	Nothing to disclose.
Mohindra, Nisha	Nothing to disclose.
Mueller, Jeff	Nothing to disclose.
Mulshine, James	Nothing to disclose.
Murgu, Tim	Nothing to Disclose.
Nagy, Andrew	Nothing to disclose.
Naqash, Abdul Rafah	Nothing to disclose.
Barrueco, Jose	Nothing to disclose.
Osarogiagbon, Ray	Nothing to disclose.



Patel, Jyoti	Speaker/Advisory Board: AbbVie.
Pham, Danh	Nothing to disclose.
Ramalingam, Sedhilynathan	Nothing to disclose.
Ramchandran, Kavitha	Nothing to disclose.
Robinson, Cliff	Nothing to disclose.
Rosenzweig, Ken	Equipment Vendors: Varian, Elekta.
Sasane, Medha	Ownership/Employment: Novartis Oncology.
Segal, Jeremy	Nothing to disclose
Sequist, Lecia	Speakers/Advisory Board : AstraZeneca, BMS, Genentech. Unpaid consulting for BI, Novartis, Merrimack, Pfizer.
Stroud, Chipman R.G.	Speakers Bureau: Genentech.
Strouse, Christopher	Nothing to disclose.
Tian, Geng	Nothing to disclose.
Tisch, Alison	Nothing to disclose.
Urbanic, Jim	Nothing to disclose.
Vokes, Everett	Speaker/Advisory Board: Amgen, AstraZeneca, Boehringer-Ingelheim, Celgene, Eli Lilly, Genentech, Merck, Synta, VentiRx.
Vokes, Everett	Speaker/Advisory Board: AbbVie, Amgen, AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Genentech, Leidos, Merck, Regeneron, Serono, Takeda, VentiRx - Consultant/Advisory Role
Wakelee, Heather	Consultant: Peregrine, ACEA, Pfizer, Helsinn, Genentech/Roche (uncompensated), Clovis (uncompensated), Lilly (uncompensated): Research/Grant Support: Clovis, Exelixis, AstraZeneca/Medimmune, Genentech/Roche, BMS, Gilead, Novartis, Xcovery, Pfizer, Celgene, Gilead, Pharmacyclics, Lilly
Walker, Paul	Speakers Bureau/Advisory Board: Biodesix; Genentech.
Winn, Robert	Nothing to disclose.
Wilshire, Candice	Nothing to disclose.
Zaidi, Zoubida	Nothing to disclose.

TO RECEIVE CME CREDIT:

Upon completion of the electronic evaluation link the **CME Certificate will be ready for you to print or save for your records**. This information is used not only to evaluate the present activity, but also to plan for future programs. Participants who complete an evaluation will receive up to 11.5 *AMA PRA Category 1 Credit(s)*[™] for each completed activity the learner has participated .



Thank you for your participation.